What are cancer patients willing to pay for prophylactic epoetin alfa?

Ortega, Ana Laura; Dranitsaris, George; Puodziunas, Anitasha

doi:10.1002/(sici)1097-0142(19981215)83:12<2588::aid-cncr26>3.0.co;2-m

Cited by 59 publications

(35 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, CV has been increasingly used in the context of health and health care. 1 Generally by eliciting respondents' willingness to pay (WTP), CV has been used to evaluate all types of preventive, diagnostic, or therapeutic care strategies, in various specific medical circumstances such as obstetrics/maternity care [16][17][18][19], cardiovascular diseases [20][21][22], obesity [23,24], cancer care [25,26], incontinence, or cervical screening [27]. WTP measures the strength of preferences through constructing a hypothetical but realistic scenario about the good or service in question and then asking respondents to state their maximum willingness to pay for it as if a market for it existed.…”

Section: Introductionmentioning

confidence: 99%

Cancer patients’ willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network

et al. 2011

View full text Add to dashboard Cite

Home blood transfusion may be an interesting alternative to hospital transfusion, especially when given with curative or palliative intent or for terminal care in advanced-stage cancer patients. However, there is limited information about patients' attitude toward this type of care. The purpose of this study was to measure French cancer patients' willingness to pay (WTP) for home blood transfusion and to analyze determinants of their choice. A contingent valuation survey was administered to 139 patients receiving transfusions in the framework of a regional home care network or in the hospital outpatient department. Participation was high (90%). Most patients (65%) had received home care, including 43% blood transfusions. Just under half of the patients gave a zero WTP, among which we identified 8 protest bidders. The median WTP for home blood transfusion was 26.5 per patient. In multivariate analysis, long home-hospital distance, poor quality of life, and previous experience of home care were identified as important factors in determining how much more patients would be willing to pay for transfusion at home. These results demonstrate the benefits of developing domiciliary services to improve patient well-being, notably for the weakest among them. The significant impact of previous home care experience on WTP is probably related to the strong involvement of physicians from the blood center and to their active contribution to a high-level homecare network. Some of our findings could be useful for policy decision-making regarding home care.

show abstract

Section: Introductionmentioning

confidence: 99%

Cancer patients’ willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Full texts were retrieved for 44 citations (the remainder being excluded as irrelevant on the basis of title and/or abstract). Five studies [114][115][116][117][118] were included following full-text screening (the remainder generally being excluded for not considering both costs and benefits). Figure 24 provides the study flow diagram for the systematic review.…”

Section: Resultsmentioning

confidence: 99%

“…l a discrete choice experiment by Ossa and colleagues 159 to ascertain the utility of anaemia-related health states and the willingness to pay for epoetin alfa l a model-based cost-effectiveness analysis by Borget and colleagues 157 of darbepoetin alfa compared with standard care without ESA use in patients with lung cancer, with an effectiveness measure related to the final Hb level achieved l a cost-consequences analysis by Reed and colleagues, 160 based on an open-label RCT of epoetin alfa once weekly and darbepoetin alfa every 2 weeks in patients with solid malignancies l a study by Casadevall and colleagues 161 of epoetin and recombinant human granulocyte colony-stimulating factor and supportive care in patients with myelodysplastic syndrome (this was excluded from this review because of concomitant treatment with G-CSF) l the studies by Ortega and colleagues 117 and Sheffield and colleagues, 118 both identified in the systematic review reported by Wilson and colleagues. 2 Tonelli and colleagues 88 noted in their discussion that ESA use leads to large incremental costs that do not tend to be significantly altered across a range of costs for RBCT.…”

Section: Assessment Of Cost-effectivenessmentioning

confidence: 99%

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

Crathorne

Huxley

Haasova

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

BackgroundAnaemia is a common side effect of cancer treatments and can lead to a reduction in quality of life. Erythropoiesis-stimulating agents (ESAs) are licensed for use in conjunction with red blood cell transfusions to improve cancer treatment-induced anaemia (CIA).ObjectiveTo investigate the effectiveness and cost-effectiveness of ESAs in anaemia associated with cancer treatment (specifically chemotherapy).Data sourcesThe following databases were searched from 2004 to 2013: The Cochrane Library, MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Web of Science, Cumulative Index to Nursing and Allied Health Literature, British Nursing Index, Health Management Information Consortium, Current Controlled Trials and ClinicalTrials.gov. The US Food and Drug Administration and European Medicines Agency websites were also searched. Bibliographies of included papers were scrutinised for further potentially includable studies.Review methodsThe clinical effectiveness review followed principles published by the NHS Centre for Reviews and Dissemination. Randomised controlled trials (RCTs), or systematic reviews of RCTs, of ESAs (epoetin or darbepoetin) for treating people with CIA were eligible for inclusion in the review. Comparators were best supportive care, placebo or other ESAs. Anaemia- and malignancy-related outcomes, health-related quality of life (HRQoL) and adverse events (AEs) were evaluated. When appropriate, data were pooled using meta-analysis. An empirical health economic model was developed comparing ESA treatment with no ESA treatment. The model comprised two components: one evaluating short-term costs and quality-adjusted life-years (QALYs) (while patients are anaemic) and one evaluating long-term QALYs. Costs and benefits were discounted at 3.5% per annum. Probabilistic and univariate deterministic sensitivity analyses were performed.ResultsOf 1457 titles and abstracts screened, 23 studies assessing ESAs within their licensed indication (based on start dose administered) were included in the review. None of the RCTs were completely aligned with current European Union licenses. The results suggest a clinical benefit from ESAs for anaemia-related outcomes and an improvement in HRQoL scores. The impact of ESAs on AEs and survival remains highly uncertain, although point estimates are lower, confidence intervals are wide and not statistically significant. Base-case incremental cost-effectiveness ratios (ICERs) for ESA treatment compared with no ESA treatment ranged from £19,429 to £35,018 per QALY gained, but sensitivity and scenario analyses demonstrate considerable uncertainty in these ICERs, including the possibility of overall health disbenefit. All ICERs were sensitive to survival and cost.LimitationsThe relative effectiveness of ESAs was not addressed; all ESAs were assumed to have equivalent efficacy. No studies were completely aligned with their European labelling beyond the starting dose evaluated. There is questionable generalisability given that the included trials were published > 20 years ago and there have been many changes to chemotherapy as well as to the quality of supportive treatment. Trial quality was moderate or poor and there was considerable unexplained heterogeneity for a number of outcomes, particularly survival, and evidence of publication bias. Adjustments were not made to account for multiple testing.ConclusionsESAs could be cost-effective when used closer to licence, but there is considerable uncertainty, mainly because of unknown impacts on overall survival.Study registrationThis study is registered as PROSPERO CRD42013005812.FundingThe National Institute for Health Research Health Technology Assessment programme.

show abstract

“…Eine kandadische Studie (Ortega et al 1998) arbeitete mit dieser These: Die Patienten waren bereit etwa 1/5 der tatsächlichen Kosten für EPO selbst zu begleichen. Die Autoren schließen daraus, dass die Bewertung nicht zugunsten von EPO getroffen werden kann.…”

Section: Literaturzitateunclassified

Erythropoietin bei Tumoran�mie. Ein Assessment

Jonas¹,

Wild²

2012

View full text Add to dashboard Cite

What are cancer patients willing to pay for prophylactic epoetin alfa?

Cited by 59 publications

References 12 publications

Cancer patients’ willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network

Cancer patients’ willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

Erythropoietin bei Tumoran�mie. Ein Assessment

Contact Info

Product

Resources

About